Janssen acquired bermekimab, a drug indicated for multiple dermatological indications
Bermekimab is in development for atopic dermatitis and hidradenitis suppurativa
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that it completed the acquisition of bermekimab along with certain employees from XBiotech Inc. for $750 million. The drug is in development for atopic dermatitis and hidradenitis suppurativa.
Bermekimab is an anti-IL-1 alpha monoclonal antibody (mAb) in Phase 2 development. The drug is in Phase 2 development for atopic dermatitis and hidradenitis suppurativa.
"Adding bermekimab to our pipeline and portfolio builds on our legacy in immuno-dermatology, while expanding our reach to two additional disease areas with immense unmet need: atopic dermatitis and hidradenitis suppurativa," said David M. Lee, Immunology Therapeutic Area Head, Janssen Research & Development.
XBiotech Inc. will also receive additional payments upon commercial authorizations. Janssen Biotech, Inc acquired the compound, Janssen Research & Development, LLC develop the product.